Austin

blue

Axios Austin Partners

Austin Alerts

Alert

Get smarter, faster on what matters in Austin with Asher Price and Nicole Cobler.

Axios Austin

Standard

A daily look at the most significant and interesting stories affecting Austin. Written by Nicole Cobler and Asher Price.

Axios Austin Thought Bubble

Thought Bubble

Austin Members

Membership

Pro Rata

Axios Pro Rata

Texas-based Colossal Biosciences, a biotech startup that made headlines for its goal to bring back the long-extinct woolly mammoth, announced this week that it has raised $200 million in Series C funding, bringing its total valuation to $10.2 billion.

Why it matters: The latest funding round makes Colossal Texas' first "decacorn" — a private company with a valuation of $10 billion or more.

Zoom in: This gives the company more runway to sign contracts with governments that are seeking to protect or replenish their biodiversity, while also letting it expand its de-extinction efforts into more species.

Colossal co-founder Ben Lamm, an Austin native, said the latest infusion of capital will help the company continue to scale its genome engineering tools, grow its employee count and expand its "de-extinction species list."

Colossal is based in Dallas and also has employees in Austin. Its spin-off company, Form Bio, a software product aimed at assisting with genomics research, is based in Austin.

Catch up quick: Colossal launched with the mission to respond to an "extinction crisis," which the company says will have cascading impacts on human health and food insecurity.

"The real promise lies not just in the technology, but also in how we might apply these tools to protect and restore endangered species and ecosystems," Beth Shapiro, chief scientific officer at the company, said in a statement.

Colossal officials say they've continued to make advancements on their mammoth, Thylacine (Tasmanian tiger), and Dodo de-extinction projects.

Follow the money: The latest Series C funding round was led by TWG Global, a holding company with investments in AI, financial services, private lending, sports and media, jointly led by Mark Walter and Thomas Tull.

Texas de-extinction startup Colossal secures $200M

The latest funding round brings Colossal's valuation to $10 billion.

Illustration of a price tag on a wooly mammoth's tusk.

Texas-based Colossal Biosciences, a biotech startup that <a class="gtmContentClick" data-vars-link-text="made headlines for its goal" data-vars-click-url="https://www.axios.com/local/austin/2022/04/28/mammoth-deextinction-spin-off-austin-software" data-vars-content-id="f897bb14-3f8b-4fdc-921e-6bd7dea5dbbe" data-vars-headline="Texas de-extinction startup Colossal secures $200M" data-vars-event-category="story" data-vars-sub-category="story" data-vars-item="in_content_link" href="https://www.axios.com/local/austin/2022/04/28/mammoth-deextinction-spin-off-austin-software" target="_self">made headlines for its goal</a> to bring back the long-extinct woolly mammoth, announced this week that it has raised $200 million in Series C funding, bringing its total valuation to $10.2 billion.Why it matters: <a class="gtmContentClick" data-vars-link-text="The latest funding round" data-vars-click-url="https://www.axios.com/2025/01/15/deextinction-colossal-biosciences-200-million" data-vars-content-id="f897bb14-3f8b-4fdc-921e-6bd7dea5dbbe" data-vars-headline="Texas de-extinction startup Colossal secures $200M" data-vars-event-category="story" data-vars-sub-category="story" data-vars-item="in_content_link" href="https://www.axios.com/2025/01/15/deextinction-colossal-biosciences-200-million" target="_self">The latest funding round</a> makes Colossal Texas&#x27; first &quot;decacorn&quot; — a private company with a valuation of $10 billion or more.

News

Latest news on Wall Street, Corporate America and financial regulation.

Business

Trump administration buys into quantum computing

National

SpaceX not the behemoth everyone thought

Elon Musk's SpaceX  IPO filing is out

OpenAI prepares confidential IPO filing

Tech private equity is "frozen"

topics

politics-policy

epstein-files

donald-trump

2026-midterm-elections

immigration

behind-the-curtain

race-and-equity

technology

privacy-tech-regulation

automation-and-ai

tiktok-news

big-tech

social-media

cybersecurity

economy

social-security

inflation

tariffs

federal-reserve

transportation

business

c-suite

retail-news

media

elon-musk

dealmaking

health

rfk-jr

drug-prices

axios-explains-abortion

public-health

world

israel

axios-explains-ukraine

iran

russia

china

energy-climate

nuclear-energy

climate-energy-policy

climate-change

extreme-weather

alternative-energy

electric-vehicles

science

emerging-tech

biomedicine

newsletters

charlotte

salt-lake-city

denver

boulder

kansas-city

austin

chicago

dallas

detroit

washington-dc

atlanta

indianapolis

nashville

nw-arkansas

columbus

richmond

san-francisco

boston

des-moines

houston

phoenix

miami

philadelphia

seattle

new-orleans

colorado-springs

huntsville

raleigh

san-antonio

twin-cities

pittsburgh

arapahoe

douglas

san-diego

tampa-bay

portland

cleveland

axios-local

axios-pro

axios-live

the-axios-show

Dan Primack

Featured stories

Trump administration buys into quantum computing

SpaceX not the behemoth everyone thought

Elon Musk's SpaceX IPO filing is out

OpenAI prepares confidential IPO filing

Tech private equity is "frozen"